Swiss CDMO Carbogen bolsters ADC production capability with $31M investment
Swiss CDMO Carbogen AMCIS, an active pharmaceutical ingredient manufacturer, revealed that it and an unnamed Japanese partner will invest 25.5 million Swiss francs ($31 million) to outfit two of Carbogen’s three domestic API facilities for production of ingredients used to make commercial antibody-drug conjugates.
Swiss CDMO Carbogen AMCIS, an active pharmaceutical ingredient manufacturer, revealed that it and an unnamed Japanese partner will invest 25.5 million Swiss francs ($31 million) to outfit two of Carbogen’s three domestic API facilities for production of ingredients used to make commercial antibody-drug conjugates.
